Updated:
BioDuro-Sundia
BioDuro-Sundia is a sponsor-backed CRDMO where 3,000 scientists execute drug programs from hit generation to commercial tablet form.
BioDuro-Sundia
BioDuro-Sundia traces its ancestry to 1998, when a team of scientists founded an integrated CRO in China to serve global pharmaceutical partners. After the 2019 carve-out from PPD and the subsequent combination with Shanghai-based Sundia, the platform was recapitalized by Advent International and Bridgepoint, two of the largest institutional investors in life-sciences services. The firm today operates as a private, sponsor-backed CRDMO executing preclinical discovery through commercial drug product — a structural departure from the founder-led, publicly traded CROs that dominate the sector. The firm deploys capital across three service lines: discovery biology and chemistry, drug-substance process R&D plus kilo-scale API manufacturing, and drug-product formulation at clinical-to-commercial volumes. Its technical scope spans small molecules, peptides, ADCs, and PROTACs, supported by specialized platforms — DNA-encoded library screening, MASH mouse models, and amorphous solid-dispersion bioavailability enhancement — that compete with standalone biotech tools companies. Confirmed production assets include kilo-scale API suites, hot-melt extrusion capacity, and on-site formulation bays for modified-release oral solids. In June 2023, BioDuro partnered with CTI Biotechnology to accelerate preclinical drug development across its San Diego and Shanghai sites (per the firm, June 2023). More recently, a joint venture with Cenra added Taiwan-based API capacity designed to hedge supply-chain concentration in mainland China (per the firm, October 2024). Staffing of 3,000 places BioDuro-Sundia among the top-ten standalone CRDMOs measured by headcount, though its private ownership mirrors the scale-first strategy Advent and Bridgepoint have executed across HLH Biopharma and Synlab. The firm operates from its San Diego headquarters and an associated lab footprint in Shanghai. In August 2024, BioDuro appointed former Roche and Novartis R&D leads Dr. Andrew Thomas and Dr. Stevan Djuric to its scientific advisory board — a signal that the sponsor base intends to keep client-facing credibility anchored in pharma-heavy drug-hunter expertise rather than generic CRO deal flow (per the firm, August 2024). No philanthropic vehicles or membership clubs are publicly tied to the operating entity. Its structural differentiator is full-stack IND enabling under a single sponsor-owned roof, bypassing the multiplatform coordination risk that plagues virtual biotech models. By housing hit-to-lead biology, gram-to-kilo API manufacturing, and oral-solid dose production inside one P&L, BioDuro-Sundia sells the promise of a single-project-manager SaaS model for small-molecule drug development — a posture that can compress preclinical timelines compared with the traditional federation of specialist CROs, though it exposes the sponsor to execution risk at every step of the chain.
General information
Firm type
Asset Manager
Year founded
1998
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Sector focus
Frequently asked questions
Who owns BioDuro-Sundia?
The firm is privately held by Advent International and Bridgepoint, two large-cap private equity sponsors that partnered to recapitalize the business in 2019 after its separation from PPD. No founder or family ownership stake is publicly disclosed. The management team reports through a board controlled by Advent and Bridgepoint appointees.
What distinguishes BioDuro-Sundia from other CROs?
It operates as a single-profit-center CRDMO that integrates discovery biology, chemistry, API manufacturing up to kilo scale, and oral-solid drug product under one management, whereas most large CROs run these as separate business units or partner networks. This full-stack model is marketed as 'IND enabling,' meaning a client can take a target from hit generation through an FDA-ready filing without switching providers.
Does BioDuro-Sundia work only with small molecules?
Historically focused on small molecules, the firm has expanded into peptides, antibody-drug conjugates, and PROTACs via its dedicated platform groups. Large-molecule development and bioanalysis services are explicitly listed on its website, though the manufacturing scale appears concentrated in small-molecule API and oral-solid dosage forms.
Where are BioDuro-Sundia's operations located?
Headquartered in San Diego, the firm maintains its principal laboratory and manufacturing presence in Shanghai. The October 2024 joint venture with Cenra adds API manufacturing capacity in Taiwan, supplementing the mainland China footprint.
Is BioDuro-Sundia a publicly traded company?
No. It has been owned by Advent International and Bridgepoint since 2019 and files no public financial statements. Revenue and AUM figures are not publicly disclosed.
What investment stages does BioDuro-Sundia support?
The firm's internal 'Solution Engine' and DNA-encoded library platforms target hit identification and lead optimization for preclinical biotechs, while its kilo-scale API and drug-product suites carry programs through clinical manufacturing and commercial launch readiness. This spans the continuum from discovery to post-approval supply.
Does BioDuro-Sundia participate in fund commitments or direct deals?
BioDuro-Sundia is an operating CRDMO, not an investment vehicle. It does not maintain a corporate venture arm. Its sponsors, Advent and Bridgepoint, handle investment activity, and BioDuro forms commercial partnerships — such as the CTI Biotechnology and Cenra collaborations — rather than taking equity positions in client biotechs.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: